Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 1/7/2020
SIETES contiene 93059 citas

 
 
 1 a 20 de 262 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Addis A, Ganazzani A, Trotta MP, Magrini N, for the Italian Medicines Agency Scientific Committee and COVID-19 Crisis Unit. Promoting better clinical trials and drug information as public health interventions for the COVID-19 emergency in Italy. Ann Intern Med 2020:16 de junio. [Ref.ID 103673]
2.Enlace a cita originalTiene citas relacionadas
Smith EMD, Foster HE, Beresford MW. The development and assessment of biological treatments for children. Br J Clin Pharmacol 2015;79:379-94. [Ref.ID 98956]
3.Enlace a cita originalTiene citas relacionadas
Joseph PD, Craig JC, Caldwell PHY. Clinical trials in children. Br J Clin Pharmacol 2015;79:357-69. [Ref.ID 98955]
4.Tiene citas relacionadas
Sacks LV, Shamsuddin HH, Yasinskaya YI, Bouri K, Lanthier ML, Sherman RE. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012. JAMA 2014;311:378-84. [Ref.ID 97049]
5.Tiene citas relacionadas Cita con resumen
Downing NS, Aminawung JA, Shah ND, Krumholz HM, Ross JS. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. JAMA 2014;311:368-77. [Ref.ID 97048]
8. Cita con resumen
Mills EJ, Ioannidis JPA, Thorlund K, Schünemann HJ, Puhan MA, Guyatt GH. How to use an article reporting a multiple treatment comparison meta-analysis. JAMA 2012;308:1246-53. [Ref.ID 93801]
9.Tiene citas relacionadas Cita con resumen
Evans SJW. An agenda for UK clinical pharmacology: pharmacoepidemiology. Br J Clin Pharmacol 2012;73:973-8. [Ref.ID 93098]
10.Enlace a cita original Cita con resumen
Fraga Fuentes MD, Tenías Burillo JM, Ruiz Martín de la Torre R, López Sánchez P, Jerez Fernández E, Valenzuela Gámez JC. Dar sentido a las evidencias: aspectos claves a valorar en los ensayos clínicos sobre medicamentos. Boletín Farmacoterapéutico de Castilla-La Mancha 2012;23:1-8. [Ref.ID 92717]
11.Enlace a cita original
Fraga Fuentes MD, Tenías Burillo JM, Ruiz R, López P, Jerez E, Valenzuela JC. Dar sentido a evidencias: aspectos claves a valorar en los ensayos clínicos sobre medicamentos.. Boletín Farmacoterapéutico de Castilla-La Mancha 2012;13:1-8. [Ref.ID 92704]
12.
Morris MC, Tangney CC. A potential design flaw of randomized trials of vitamin supplements. JAMA 2011;305:1348-9. [Ref.ID 90452]
13.
Fleming TR. Addressing missing data in clinical trials. Ann Intern Med 2011;154:113-7. [Ref.ID 90060]
14. Cita con resumen
Psaty BM, Prentice RL. Minimizing bias in randomized trials. The importance of blinding. JAMA 2010;304:793-4. [Ref.ID 89149]
15. Cita con resumen
Chalmers I. Explaining the unbiased creation of treatment comparison groups. Lancet 2009;374:1670-1. [Ref.ID 87078]
16. Cita con resumen
Bland JM. The tyranny of power: is there a better way to calculate the sample size?. BMJ 2009;339:1133-5. [Ref.ID 87077]
17. Cita con resumen
Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. Lancet 2009;374:86-9. [Ref.ID 86288]
18. Cita con resumen
Wise J. High rate of flawed trials found in Chinese medical journals. BMJ 2009;339:71. [Ref.ID 86237]
19. Cita con resumen
Monleón-Getino T, Barnadas-Molins A, Roset-Gamisans M. Diseños secuenciales y análisis intermedio en la investigación clínica: tamaño frente a dificultad. Med Clin (Barc) 2009;132:437-42. [Ref.ID 85552]
20.Tiene citas relacionadas
Tyrer P, Kendall T. Atypical antipsychotic drugs have their merits. Authors' reply. Lancet 2009;373:1007-8. [Ref.ID 85507]
Seleccionar todas
 
 1 a 20 de 262 siguiente >>